LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE

This disclosure relates to methods of treating interstitial lung disease by administering (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid (a LPA1 antagonist). La présente divulgation concerne des méthodes...

Full description

Saved in:
Bibliographic Details
Main Authors TIRUCHERAI, Giridhar S, FISCHER, Aryeh, TAO, Shiwei, CHARLES, Edgar D
Format Patent
LanguageEnglish
French
Published 27.06.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This disclosure relates to methods of treating interstitial lung disease by administering (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid (a LPA1 antagonist). La présente divulgation concerne des méthodes de traitement d'une pneumopathie interstitielle par administration d'acide (1S,3S)-3-((2-méthyl-6-(1-méthyl-5-(((méthyl(propyl)carbamoyl)oxy)méthyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylique (un antagoniste LPA1).
Bibliography:Application Number: WO2023US85749